Taletrectinib Displays Efficacy, Tolerability in ROS1+ NSCLC in Multiple Clinical Trials
Investigators hope to add a treatment option that has the potential to produce superior efficacy vs present ROS1 inhibitors for patients with ROS1+ NSCLC.
Related Articles
ZUMA-2 Data Support Earlier-Line Role for Brexu-Cel in High-Risk R/R MCL Subgroups
Tom van Meerten, MD, PhD, discusses key efficacy and safety data with brexu-cel in BTK inhibitor–naive relapsed/refractory mantle cell lymphoma.
Victoria’s Secret Global Fund for Women’s Cancers Career Development Awards, in Partnership with Pelotonia & AACR
$206,000 over two years for female assistant professors conducting research with a direct applicability and relevance to the understanding, prevention, interception, early detection, diagnosis, or…
OCE Conversations on Cancer – Cervical Cancer Treatment Innovation: A Collaborative Discussion
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Outcomes of Neoadjuvant Chemotherapy for Invasive Intraductal Papillary Mucinous Neoplasm Compared with de Novo Pancreatic Adenocarcinoma
Annals of Surgical Oncology – The management of invasive intraductal papillary mucinous cystic neoplasm (I-IPMN) does not differ from de novo pancreatic ductal adenocarcinoma (PDAC);…
Odronextamab Monotherapy Shows Encouraging Efficacy, Manageable Safety for DLBCL Progressing After CAR-T Therapy
Matthew Matasar, MD, discusses results from a primary analysis of the ELM-1 study that showed the encouraging efficacy and manageable safety of CD20-CD3 bispecific antibody…
Enfortumab Vedotin Demonstrates Real-World Efficacy Among Patients With Metastatic Urothelial Carcinoma
According to results from a retrospective study, single-agent enfortumab vedotin demonstrated real-world efficacy among previously treated patients with metastatic urothelial carcinoma.
The METACER national cohort study of brain metastases in gastrointestinal cancers prospectively establishes prognostic factors
Journal of Neuro-Oncology – Availability data are scarce and primarily retrospective in patients with brain metastasis (BM) from gastrointestinal (GI) cancers. The objective of this…
Second-Line Axi-Cel Is Efficacious, Safe in Real-World Patients With R/R LBCL
Dasom (Caroline) Lee, MD, discusses real-world data for second-line axi-cel in relapsed/refractory large B-cell lymphoma.
Down with dex!
In this issue of Blood, Banerjee et al1 present a secondary analysis of pooled data from 2 completed SWOG cooperative group trials (SO777 and S1211), showi
2024 ARC Amyloidosis Community Survey
ARC is conducting an online survey of patients and caregivers for individuals living with amyloidosis to collect data and information on …
